Comparison of inflammatory markers for the prediction of neointimal hyperplasia after drug-eluting stent implantation

Coronary Artery Disease

Volumn 22, Issue 8, 2011, Pages 526-532

  Kang, Woong Chol ^a   Moon, Chan Il ^a   Lee, Kyounghoon ^a   Han, Seung Hwan ^a   Suh, Soon Yong ^a   Moon, Jeonggeun ^a   Shin, Mi Seung ^a   Ahn, Taehoon ^a   Shin, Eak Kyun ^a  

^a Gachon University   (South Korea)

Author keywords

High sensitivity C reactive protein; interleukin 6; intravascular ultrasound; matrix metalloproteinase 9; neointimal hyperplasia

Indexed keywords

C REACTIVE PROTEIN; GELATINASE B; INTERLEUKIN 6;

ADULT; AGED; ANGIOCARDIOGRAPHY; ARTICLE; CLINICAL TRIAL; COMPARATIVE STUDY; DRUG ELUTING STENT; FEMALE; HUMAN; HYPERPLASIA; INTRAVASCULAR ULTRASOUND; MAJOR CLINICAL STUDY; MALE; NEOINTIMA; NEOINTIMAL HYPERPLASIA; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; PROSPECTIVE STUDY; STABLE ANGINA PECTORIS;

AGED; ANALYSIS OF VARIANCE; ANGIOPLASTY, BALLOON, CORONARY; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; CORONARY ANGIOGRAPHY; CORONARY RESTENOSIS; CORONARY VESSELS; DRUG-ELUTING STENTS; FEMALE; HUMANS; HYPERPLASIA; INFLAMMATION; INFLAMMATION MEDIATORS; INTERLEUKIN-6; LINEAR MODELS; MALE; MATRIX METALLOPROTEINASE 9; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; PROSPECTIVE STUDIES; PROSTHESIS DESIGN; REPUBLIC OF KOREA; RISK ASSESSMENT; RISK FACTORS; TIME FACTORS; TREATMENT OUTCOME; TUNICA INTIMA; ULTRASONOGRAPHY, INTERVENTIONAL;

EID: 81855212779     PISSN: 09546928     EISSN: 14735830     Source Type: Journal    
DOI: 10.1097/MCA.0b013e32834bd946     Document Type: Article

References (35)

1. Kornowski R, Hong MK,Tio FO, Bramwell O, Wu H, Leon MB. In-stent restenosis: contributions of inflammatory responses and arterial injury to neointimal hyperplasia. JAm Coll Cardiol1998; 31:224-230. (Pubitemid 28064746)
2. Farb A, Weber DK, Kolodgie FD, Burke AP, Virmani R. Morphological predictors of restenosis after coronary stenting in humans. Circulation 2002; 105:2974-2980. (Pubitemid 34693829)
3. Forrester JS, Fishbein M, Helfant R, Fagin J. A paradigm for restenosis based on cell biology: clues for the development of new preventive therapies. J Am Coll Cardiol 1991; 17:758-769.
4. Okamoto E, Couse T, De Leon H, Vinten-Johansen J, Goodman RB, Scott NA, etal. Perivascular inflammation after balloon angioplasty of porcine coronary arteries. Circulation 2001; 104:2228-2235. (Pubitemid 33043305)
5. Chew DP, Bhatt DL, Robbins MA, Penn MS, Schneider JP, Lauer MS, et al. Incremental prognostic value of elevated baseline C-reactive protein among established markers of risk in percutaneous coronary intervention. Circulation 2001; 104:992-997. (Pubitemid 32803874)
6. de Winter RJ, Heyde GS, Koch KT, Fischer J, Van Straalen JP, Bax M, Schotborgh CE. The prognostic value of pre-procedural plasma C-reactive protein in patients undergoing elective coronary angioplasty. Eur Heart J 2002; 23:960-966. (Pubitemid 35203875)
7. Pietersma A, Kofflard M, de Wit LE, Stijnen T, Koster JF, Serruys PW, et al. Late lumen loss after coronary angioplasty is associated with the activation status of circulating phagocytes before treatment. Circulation 1995; 91:1320-1325.
8. Walter DH, Fichtlscherer S, Sellwig M, Auch-Schwelk W, Schachinger V, Zeiher AM. Preprocedural C-reactive protein levels and cardiovascular events after coronary stent implantation. JAm Coll Cardiol 2001; 37:839-846. (Pubitemid 32202453)
9. Zairis MN, Ambrose JA, Manousakis SJ, Stefanidis AS, Papadaki OA, Bilianou HI, et al. The impact of plasma levels of C-reactive protein, lipoprotein (a) and homocysteine on the long-term prognosis after successful coronary stenting: the global evaluation of new events and restenosis after stent implantation study. JAm Coll Cardiol 2002; 40: 1375-1382. (Pubitemid 35192859)
10. Bendeck MP, Irvin C, Reidy MA. Inhibition of matrix metalloproteinase activity inhibits smooth muscle cell migration but not neointimal thickening after arterial injury. Circ Res 1996; 78:38-43. (Pubitemid 26004118)
11. Dollery CM, Mc Ewan JR, Henney AM. Matrix metalloproteinases and cardiovascular disease. Circ Res 1995; 77:863-868.
12. Gaspardone A, Crea F, Versaci F, Tomai F, Pellegrino A, Chiariello L, et al. Predictive value of C-reactive protein after successful coronary-artery stenting in patients with stable angina. Am J Cardiol1998; 82:515-518. (Pubitemid 28389953)
13. Kim JY, Ko YG, Shim CY, Park S, Hwang KC, Choi D, et al. Comparison of effects of drug-eluting stents versus bare metal stents on plasma C-reactive protein levels. Am J Cardiol 2005; 96:1384-1388. (Pubitemid 41566618)
14. Abbate A, Biondi-Zoccai GG, Brugaletta S, Liuzzo G, Biasucci LM. C-reactive protein and other inflammatory biomarkers as predictors of outcome following acute coronary syndromes. Semin Vasc Med 2003; 3:375-384.
15. Biasucci LM, Liuzzo G, Grillo RL, Caligiuri G, Rebuzzi AG, Buffon A, etal. Elevated levels of C-reactive protein at discharge in patients with unstable angina predict recurrent instability. Circulation 1999; 99:855-860. (Pubitemid 29094296)
16. Morrow DA, Rifai N,Antman EM,Weiner DL, Mc Cabe CH, Cannon CP, etal. C-reactive protein is a potent predictor of mortality independently of and in combination with troponin T in acute coronary syndromes: a TIMI 11A substudy. Thrombolysis in myocardial infarction. JAm Coll Cardiol1998; 31:1460-1465. (Pubitemid 28273285)
17. Mueller C, Buettner HJ, Hodgson JM, Marsch S, Perruchoud AP, Roskamm H, et al. Inflammation and long-term mortality after non-ST elevation acute coronary syndrome treated with a very early invasive strategy in 1042 consecutive patients. Circulation 2002; 105:1412-1415. (Pubitemid 34263269)
18. Pearson TA, Mensah GA, Alexander RW, Anderson JL, Cannon RO III, Criqui M, etal. Markers of inflammation and cardiovascular disease: application to clinical and public health practice. A statement for healthcare professionals from the centers for disease control and prevention and the American Heart Association. Circulation 2003; 107:499-511. (Pubitemid 36158056)
19. Ridker PM. Clinical application of C-reactive protein for cardiovascular disease detection and prevention. Circulation 2003; 107:363-369. (Pubitemid 36158034)
20. Zebrack JS, Muhlestein JB, Horne BD, Anderson JL. C-reactive protein and angiographic coronary artery disease: independent and additive predictors of risk in subjects with angina. J Am Coll Cardiol 2002; 39:632-637. (Pubitemid 34158159)
21. Choi SY,Tahk SJ,Yoon MH, Choi JH, Kim MC, Zheng Z, etal. Preprocedural hs-CRP level serves as a marker for procedure-related myocardial injury during coronary stenting. Korean Circ J 2005; 35:140-148.
22. Buffon A, Liuzzo G, Biasucci LM, Pasqualetti P, Ramazzotti V, Rebuzzi AG, et al. Preprocedural serum levels of C-reactive protein predict early complications and late restenosis after coronary angioplasty. J Am Coll Cardiol 1999; 34:1512-1521. (Pubitemid 29528666)
23. Jeong WK, Jeong MH, Kim KH, Lee SR, Park OY,Yum JH, etal. An elevated value of C-reactive protein is the only predictive factor of restenosis after percutaneous coronary intervention. Korean J Intern Med 2003; 18: 154-160.
24. Segev A, Kassam S, Buller CE, Lau HK, Sparkes JD, Connelly PW, et al. Pre-procedural plasma levels of C-reactive protein and interleukin-6 do not predict late coronary angiographic restenosis after elective stenting. Eur Heart J 2004; 25:1029-1035. (Pubitemid 38869421)
25. Hong YJ, Jeong MH, Lim SY, Lee SR, Kim KH, Sohn IS, etal. Elevated preprocedural high-sensitivity C-reactive protein levels are associated with neointimal hyperplasia and restenosis development after successful coronary artery stenting. Circ J 2005; 69:1477-1483.
26. Gottsauner-Wolf M, Zasmeta G, Hornykewycz S, Nikfardjam M, Stepan E, Wexberg P, et al. Plasma levels of C-reactive protein after coronary stent implantation. Eur Heart J 2000; 21:1152-1158. (Pubitemid 30438640)
27. Dibra A, Mehilli J, Braun S, Hadamitzky M, Baum H, Dirschinger J, et al. Association between C-reactive protein levels and subsequent cardiac events among patients with stable angina treated with coronary artery stenting. Am J Med 2003; 114:715-722. (Pubitemid 36776352)
28. Hojo Y, Ikeda U, Katsuki T, Mizuno O, Fukazawa H, Kurosaki K, et al. Interleukin 6 expression in coronary circulation after coronary angioplasty as a risk factor for restenosis. Heart 2000; 84:83-87. (Pubitemid 30429230)
29. Gomma AH, Hirschfield GM, Gallimore JR Jr, Lowe GD, Pepys MB, Fox KM. Preprocedural inflammatory markers do not predict restenosis after successful coronary stenting. Am Heart J2004; 147:1071-1077. (Pubitemid 38880967)
30. Suzuki T, Ishiwata S, Hasegawa K, Yamamoto K, Yamazaki T. Raised interleukin 6 concentrations as a predictor of postangioplasty restenosis. Heart 2000; 83:578. (Pubitemid 30316729)
31. Cedro K, Radomski A, Radomski MW, Ruzyllo W, Herbaczynska-Cedro K. Release of matrix metalloproteinase-9 during balloon angioplasty in patients with stable angina: a preliminary study. Int J Cardiol 2003; 92:177-180. (Pubitemid 37509979)
32. Zemlianskaia OA, Panchenko EP, Samko AN, Dobrovol'skii AB, Levitskii IV, Masenko VP, et al. Matrix metalloproteinases, C-reactive protein, and markers of thrombinemia in patients with stable angina and restenoses after percutaneous coronary interventions. Kardiologiia 2004; 44:4-12.
33. Ge J, Shen C, Liang C, Chen L, Qian J, Chen H. Elevated matrix metalloproteinase expression after stent implantation is associated with restenosis. Int JCardiol2006; 112:85-90. (Pubitemid 44247183)
34. Blankenberg S, Rupprecht HJ, Poirier O, Bickel C, Smieja M, Hafner G, et al. Plasma concentrations and genetic variation of matrix metalloproteinase 9 and prognosis of patients with cardiovascular disease. Circulation 2003; 107:1579-1585. (Pubitemid 36397324)
35. Zouridakis E, Avanzas P, Arroyo-Espliguero R, Fredericks S, Kaski JC. Markers of inflammation and rapid coronary artery disease progression in patients with stable angina pectoris. Circulation 2004; 110:1747-1753. (Pubitemid 39299216)